Referred to the House Committee on Energy and Commerce.
This bill reauthorizes the National Diabetes Prevention Program by amending the Public Health Service Act. It replaces prior open‑ended language and specifies annual appropriations of $39.3M (FY2027), $44.3M (FY2028), $49.3M (FY2029), $54.3M (FY2030), and $59.3M (FY2031).
Liberal emphasizes public‑health benefits and equity requirements.
Relative to its intended legislative type, this bill is narrowly focused and well-specified as a statutory reauthorization: it precisely amends the identified statutory subsection and sets explicit authorized funding levels for five fiscal years.
This bill reauthorizes the National Diabetes Prevention Program by amending the Public Health Service Act.
It replaces prior open‑ended language and specifies annual appropriations of $39.3M (FY2027), $44.3M (FY2028), $49.3M (FY2029), $54.3M (FY2030), and $59.3M (FY2031).
The law simply sets funding levels for the program through FY2031.
Modest, targeted reauthorization with bipartisan appeal improves chances, but enactment depends on later appropriations and legislative calendar.
Relative to its intended legislative type, this bill is narrowly focused and well-specified as a statutory reauthorization: it precisely amends the identified statutory subsection and sets explicit authorized funding levels for five fiscal years. It does not provide explanatory context, additional implementation steps, new oversight or reporting requirements, or fiscal offsets.
Liberal emphasizes public‑health benefits and equity requirements.
These are examples from the analysis, not a ranked list of the most-affected groups.
Liberal emphasizes public‑health benefits and equity requirements.
Generally supportive: views federal reauthorization and steady funding as a needed public health investment.
Would likely press for stronger equity, access, and accountability provisions.
Cautiously supportive: sees this as reasonable, incremental public health spending with bipartisan appeal.
Wants clearer oversight, cost-effectiveness data, and budget offsets or limits.
Skeptical: supports prevention in principle but objects to expanded federal funding and recurring spending without offsets.
Prefers state, private, or market approaches.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Modest, targeted reauthorization with bipartisan appeal improves chances, but enactment depends on later appropriations and legislative calendar.
The bill has not accumulated any surfaced votes yet.
Liberal emphasizes public‑health benefits and equity requirements.
Modest, targeted reauthorization with bipartisan appeal improves chances, but enactment depends on later appropriations and legislative cal…
Relative to its intended legislative type, this bill is narrowly focused and well-specified as a statutory reauthorization: it precisely amends the identified statutory subsection and sets explicit authorized funding le…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.